Journal of Antimicrobial Chemotherapy (2002) 50, 219-224
© 2002 The British Society for Antimicrobial Chemotherapy
Influence of grapefruit juice on itraconazole plasma levels in mice and guinea pigs
Department of Molecular and Cell Biology, Institute of Medical Sciences, Foresterhill, University of Aberdeen, Aberdeen AB25 2ZD, UK
Received 15 October 2001; returned 28 March 2002; revised 18 April 2002; accepted 26 April 2002
Levels of itraconazole and its metabolite hydroxy-itraconazole were measured by HPLC in plasma samples from guinea pigs and DBA/2 and BALB/c mice after oral or intraperitoneal treatment with itraconazole/cyclodextrin solution at 5 and 20 mg/kg daily for 7 days. The animals were randomly assigned to receive grapefruit juice or drinking water in their fluid bottles, since components of grapefruit juice have been found to alter the pharmacokinetic behaviour of pharmaceuticals that interact with cytochrome P450 enzymes. The results demonstrated clear differences in itraconazole pharmacokinetics between the three animal types studied. The total levels of antifungally active azole were highest in DBA/2 mice and lowest in guinea pigs, regardless of the route of administration. Guinea pigs that drank grapefruit juice had higher plasma levels of azoles after oral administration of the drug, but the juice did not influence levels of itraconazole or its metabolite in guinea pigs treated intraperitoneally, or in either mouse strain treated orally or intraperitoneally. This result indicates that grapefruit juice effects on the pharmacokinetics of itraconazole are species dependent and confined to the gastrointestinal tract, influencing drug absorption. Differences in itraconazole pharmacokinetics between mouse strains need to be considered in the design of experiments involving itraconazole treatment of mice experimentally infected with fungi.
* Corresponding author. Tel: +44-1224-273128; Fax: +44-1224-273144; E-mail: f.odds{at}abdn.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Meletiadis, S. Chanock, and T. J. Walsh Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy Clin. Microbiol. Rev., October 1, 2006; 19(4): 763 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Capilla and J. Guarro Correlation between In Vitro Susceptibility of Scedosporium apiospermum to Voriconazole and In Vivo Outcome of Scedosporiosis in Guinea Pigs Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4009 - 4011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Capilla, C. Serena, F. J. Pastor, M. Ortoneda, and J. Guarro Efficacy of Voriconazole in Treatment of Systemic Scedosporiosis in Neutropenic Mice Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3976 - 3978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Graybill, L. K. Najvar, G. M. Gonzalez, S. Hernandez, and R. Bocanegra Improving the mouse model for studying the efficacy of voriconazole J. Antimicrob. Chemother., June 1, 2003; 51(6): 1373 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. MacCallum and F. C. Odds Efficacy of parenteral itraconazole against disseminated Candida albicans infection in two mouse strains J. Antimicrob. Chemother., August 1, 2002; 50(2): 225 - 229. [Abstract] [Full Text] [PDF]
|
|